Plain-English translation of NCT06289062 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining standard chemotherapy with a drug called —which helps your immune system fight cancer—can shrink early-stage cervical cancer effectively enough that surgery can be limited to preserve your ability to have children in the future. The study will track how well the treatment works, any side effects, and whether women who participate are able to become pregnant and have healthy babies after treatment.
Women diagnosed with early-stage cervical cancer often face a difficult choice: standard treatment involves surgery that removes the entire cervix, which usually means losing the ability to have biological children. This trial exists to see if this medication, combined with chemotherapy, might shrink tumors enough that less extensive surgery or other options could be used instead, giving women more choices about their fertility.
You likely qualify if…
You likely don't qualify if…
You would receive one round of chemotherapy, then two more rounds of chemotherapy combined with over about nine weeks. After treatment ends, doctors will perform a biopsy to check if the cancer has shrunk enough to preserve your cervix. If criteria are met, you'll have follow-up visits at 3 months and beyond to monitor your cervix with imaging and testing. The trial will then track your health and pregnancy outcomes for years to come.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China